{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:16:04Z","timestamp":1792034164067,"version":"4.4.0"},"reference-count":98,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the context of rare genetic diseases caused by nonsense mutations, the concept of induced stop codon readthrough (SCR) represents an attractive avenue in the ongoing search for improved treatment options. Epidermolysis bullosa (EB)\u2014exemplary for this group of diseases\u2014describes a diverse group of rare, blistering genodermatoses. Characterized by extreme skin fragility upon minor mechanical trauma, the most severe forms often result from nonsense mutations that lead to premature translation termination and loss of function of essential proteins at the dermo\u2010epidermal junction. Since no curative interventions are currently available, medical care is mainly limited to alleviating symptoms and preventing complications. Complementary to attempts of gene, cell and protein therapy in EB, SCR represents a promising medical alternative. While gentamicin has already been examined in several clinical trials involving EB, other potent SCR inducers, such as ataluren, may also show promise in treating the hitherto non\u2010curative disease. In addition to the extensively studied aminoglycosides and their derivatives, several other substance classes\u2014non\u2010aminoglycoside antibiotics and non\u2010aminoglycoside compounds\u2014are currently under investigation. The extensive data gathered in numerous in\u00a0vitro experiments and the perspectives they reveal in the clinical setting will be discussed in this review.<\/jats:p>","DOI":"10.1111\/exd.15042","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T04:43:25Z","timestamp":1709959405000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Stop codon readthrough as a treatment option for epidermolysis bullosa\u2014Where we are and where we are going"],"prefix":"10.1111","volume":"33","author":[{"given":"Johanna","family":"Zandanell","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergology University Hospital of the Paracelsus Medical University  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wie\u00dfner","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology University Hospital of the Paracelsus Medical University  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann W.","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology University Hospital of the Paracelsus Medical University  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-240X","authenticated-orcid":false,"given":"Roland N.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology University Hospital of the Paracelsus Medical University  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0210-0"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18921"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.052"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.053"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12774"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.161190"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.01.903"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18128"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.11.021"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.2473"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17012"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20958"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18637"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13762"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18826"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.12404"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00561-5"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2014.05.001"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2014.10.027"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1995.0438"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.12.5431"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr224"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10165"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03060"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52611"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0496-467"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.07.007"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-091212-153527"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.11.3133"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp1253"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/937861"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2011.00728.x"},{"issue":"2","key":"e_1_2_12_34_1","first-page":"151","article-title":"Drug\u2010mediated ototoxicity and tinnitus: alleviation with melatonin","volume":"62","author":"Reiter RJ","year":"2011","journal-title":"J Physiol Pharmacol"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2006.11.012"},{"issue":"4","key":"e_1_2_12_36_1","first-page":"352","article-title":"Use of poly\u2010l\u2010aspartic acid to inhibit aminoglycoside cochlear ototoxicity","volume":"14","author":"Hulka GF","year":"1993","journal-title":"Am J Otol"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1990.258.6.C1141"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.3.333"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15230"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1803154115"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0112"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13912"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1365\/s10337-010-1763-y"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/bf02464911"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1017\/s1355838200000716"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1023474719042"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2010.03.060"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.01.009"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.09.020"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2017.1285480"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.647"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.914"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.09.018"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature18611"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01489"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab194"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101546"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2018.06.011"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13936"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201402-0385CI"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.169805"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114968"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-015-1364-1"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.3233\/jnd-170230"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32557"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2077"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05756"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006297140"},{"key":"e_1_2_12_69_1","unstructured":"PTC Therapeutics.Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren (NCT03648827). Accessed May 13 2023 https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03648827?term=ataluren&draw=2&rank=2"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094883"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073541"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017739"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040886"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909141107"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001593"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118766"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-58"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.011"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200525090-00001"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1261\/rna.060236.116"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067609"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1159\/000513260"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2018.01.004"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI92707"},{"key":"e_1_2_12_86_1","unstructured":"WoodleyD.Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients (NCT02698735). Accessed May 14 2023 https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02698735?term=NCT02698735&draw=2&rank=1"},{"key":"e_1_2_12_87_1","unstructured":"WoodleyD.Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa Patients With Nonsense Mutations (NCT03012191). Accessed May 14 2023 https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03012191?term=readthrough&cond=epidermolysis&draw=1&rank=4&view=record"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.03.006"},{"key":"e_1_2_12_89_1","unstructured":"WoodleyD.A Pilot Study of the Restoration of Functional Laminin 332 in JEB Patients With Nonsense Mutations After Topical and Intravenous Gentamicin Treatment (NCT03526159). Accessed May 14 2023 https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03526159?term=NCT03526159&draw=2&rank=1"},{"key":"e_1_2_12_90_1","unstructured":"WoodleyD.Optimization of Intravenous Gentamicin Treatment to Restore Functional Laminin 332 in JEB Patients With Nonsense Mutations (NCT04140786). Accessed May 14 2023 https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04140786"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5992"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1159\/000499906"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2020.97072"},{"key":"e_1_2_12_94_1","unstructured":"Sandanger\u00d8.Topical gentamicin treatment of patients with epidermolysis bullosa due to nonsense mutations (NCT04644627). Accessed May 14 2023 https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04644627?recrs=abdefghim&cond=Epidermolysis+Bullosa&draw=2"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_554_21"},{"key":"e_1_2_12_96_1","unstructured":"WoodleyD.Restoration of Full\u2010Length Type VII Collagen in RDEB Patients With Nonsense Mutations After Intravenous Gentamicin Treatment (NCT03392909). Accessed May 14 2023 https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03392909"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.58"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.05.010"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.140"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.15042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T09:03:12Z","timestamp":1734771792000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.15042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/exd.15042"],"URL":"https:\/\/doi.org\/10.1111\/exd.15042","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2023-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15042"}}